Lenvatinb

DRUG3 trials

Sponsors

Sun Yat-sen University, Zhejiang Haichang Biotech Co., Ltd., Vall d'Hebron Institute of Oncology

Conditions

AblationAdvanced Hepatocellular Carcinoma (HCC)LenvatinibLocal TherapyRecurrent Hepatocellular CarcinomaRenal Cell CarcinomaSystemic Therapy

Phase 1

A Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC

Not yet recruitingNCT07540832

Zhejiang Haichang Biotech Co., Ltd.Advanced Hepatocellular Carcinoma (HCC)

Start: 2026-09-01End: 2028-10-01Target: 80Updated: 2026-09-15

Phase 2

Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma

Not yet recruitingNCT07593040

Vall d'Hebron Institute of OncologyRenal Cell Carcinoma

Start: 2026-06-01End: 2031-06-01Target: 150Updated: 2026-05-20

Unknown Phase

The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma

RecruitingNCT06609850

Sun Yat-sen UniversityAblation, Lenvatinib, Local Therapy +2

Start: 2024-10-01End: 2028-10-30Target: 116Updated: 2024-12-03